As the inhibition of ERG could possibly benefit the survival of MLL-rearranged ALL patients as well as patients suffering from AML and T-ALL, this gene represents an interesting candidate target gene for therapeutic intervention. The gene discussed is KMT2A; the disease is acute lymphoblastic leukemia.